Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Hims & Hers Health (HIMS) · oqro.io/stocks/HIMS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Hims & Hers Health insider trading
Have Hims & Hers Health insiders bought shares recently?
No open-market purchase by an insider of Hims & Hers Health was filed in the last 90 days. The latest on record was on May 26, 2026.
How often do Hims & Hers Health insiders buy and sell shares?
Since 2021, Hims & Hers Health insiders reported 14 open-market purchases and 603 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2026.
Who is selling Hims & Hers Health stock?
In the last 90 days, 5 insiders of Hims & Hers Health (HIMS) reported 13 open-market sales worth $3.05M in total on SEC Form 4. The largest seller by value was Oluyemi Okupe, with $1.36M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade HIMS?
No trade in Hims & Hers Health (HIMS) was disclosed by a member of Congress in the last 12 months.
When does Hims & Hers Health report its next results?
Hims & Hers Health's next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−56.6% (−$19.02) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $33.62 on Nov 20, 2025 to $14.60 on Nov 20, 2026 (−56.6%). Disclosed in this range: 2 insider trades, 46 pre-arranged insider sales, 0 Congress trades, and 17 13F position changes for 4 quarters ending in it.
$10$20$30$40$50$14.60
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 48 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Services company based in San Francisco, California.
Last 12 months
−56.6%
S&P 500 +5.7% over the same dates
Market value
$4.33B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 51.7M shares sold short (17.4% of shares outstanding), −3.4% vs the previous count, 5.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$890M
+48.6% vs the same quarter a year earlier
Free cash flow, last 12 months
$8.22M
This quarter $26M, a year earlier $79.4M
Net debt
—
Debt —, cash $606M, at Sep 30, 2026
Net income, last 12 months
−$191M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 9, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 30 days
Written by software from the filings listed below · Oct 26, 2026
Insiders. In the 30 days to Oct 26, 2026, insiders filed 0 open-market purchases and 3 open-market sales, about $261K, in 3 filings by 2 people. Hims & Hers Health on OQRO
3 more points, with the facts they come from, are in OQRO Pro.
Insiders of Hims & Hers Health reported 14 open-market purchases and 603 sales since 2021; purchases in 4 different years, most recently 2026.
Year
Bought
Sold
2026
$1.17M1×1 trade
$16.5M40×40 trades
2025
—
$194M200×200 trades
2024
$2.08M3×3 trades
$142M229×229 trades
2023
—
$42M91×91 trades
2022
$508K5×5 trades
$1.97M22×22 trades
2021
$3.45M5×5 trades
$9.09M21×21 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Red flags in its filings
Oct 7
Top officer leaving
“Franklin as principal accounting officer of the Company, effective October 9, 2026, concurrently with the previously disclosed resignation of Irene Becklund as the Company's principal accounting officer.”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Hims & Hers Health filed 1 open-market purchase (about $1.17M, in 1 filing, by 1 person) and 47 open-market sales (about $19M, in 44 filings, by 8 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 224 open-market sales (about $208M, in 108 filings). (Hims & Hers Health on OQRO)
Congress. Members of Congress filed 0 disclosures on Hims & Hers Health in the 12 months to Nov 19, 2026: 0 purchases and 0 sales, by 0 members. In the 12 months before that: 1 disclosure.
Funds and stakes. Fund 13F filings recorded in the 12 months show 9 new or larger positions and 9 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter. G1 Execution Services, LLC cut its HIMS stake below 5% (4.8%) (filed Nov 16, 2026).
Contracts, lobbying and filings. FINRA short interest for HIMS on the settlement date of Oct 30, 2026 was 51,657,110 shares (-3.4% on the previous report), about 5.84 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 75,299 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Hims & Hers Health filed a Form 8-K on Nov 9, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member. The company's own opening sentence of that report reads: "On November 4, 2026, the board of directors (the 'Board') of Hims & Hers Health, Inc. (the 'Company') increased the size of the Board from nine to ten directors and appointed Dr. Andrew Huberman, 51, to fill the newly created dir..."
Who holds it. 506 funds reported a stake in Hims & Hers Health in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (18.4% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (6.8% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (6.1% of the value reported).
Attention. The English Wikipedia article on Hims & Hers Health was read about 154 times a day in the 7 days to Nov 18, 2026, against a usual 167 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Hims & Hers Health filed 1 open-market purchase (about $1.17M, in 1 filing, by 1 person) and 47 open-market sales (about $19M, in 44 filings, by 8 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 224 open-market sales (about $208M, in 108 filings).
The largest purchase: David B Wells, Director, about $1.17M, filed May 26, 2026.
The largest sale: Michael Chi, Chief Operating Officer, about $2.4M, filed Mar 18, 2026.
Congress
Members of Congress filed 0 disclosures on Hims & Hers Health in the 12 months to Nov 19, 2026: 0 purchases and 0 sales, by 0 members. In the 12 months before that: 1 disclosure.
Funds and stakes
Fund 13F filings recorded in the 12 months show 9 new or larger positions and 9 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
G1 Execution Services, LLC cut its HIMS stake below 5% (4.8%) (filed Nov 16, 2026).
Contracts, lobbying and filings
FINRA short interest for HIMS on the settlement date of Oct 30, 2026 was 51,657,110 shares (-3.4% on the previous report), about 5.84 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 75,299 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $23M for its principal executive officer, and an average of $17.5M for the other named executive officers.
Company reports, price and press
Hims & Hers Health filed a Form 8-K on Nov 9, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On November 4, 2026, the board of directors (the 'Board') of Hims & Hers Health, Inc. (the 'Company') increased the size of the Board from nine to ten directors and appointed Dr. Andrew Huberman, 51, to fill the newly created dir..."
Hims & Hers Health filed a Form 8-K on Oct 7, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On October 5, 2026, Jonathan M. Franklin commenced employment with Hims & Hers Health, Inc. (the 'Company') as chief accounting officer. On October 7, 2026, the Company's board of directors appointed Mr. Franklin as principal acc..."
Hims & Hers Health filed a Form 8-K on Jul 17, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On July 13, 2026, Irene Becklund informed Hims & Hers Health, Inc. (the 'Company') of her intention to resign as Chief Accounting Officer and Principal Accounting Officer, effective as of October 9, 2026."
HIMS closed at $17.05 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $28.15 to $17.05, a change of −39.4%.
Who holds it
506 funds reported a stake in Hims & Hers Health in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (18.4% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (6.8% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (6.1% of the value reported).
Attention
The English Wikipedia article on Hims & Hers Health was read about 154 times a day in the 7 days to Nov 18, 2026, against a usual 167 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
People read Hims & Hers Health's Wikipedia article about 150 times a day over the last week, close to the 170 on a usual day of the three months before.
May 15, 2026Busiest day: 440 views on Jul 30, 2026Nov 20, 2026
Views of the article Hims & Hers Health, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 9, 2026. Quarterly reports are not audited. Read the filing
By region
United States$657M74%
+21% on the same quarter a year earlier ($544M)
Non-US$233M26%
+321% on the same quarter a year earlier ($55.5M)
Total revenue$890M+49%
The full fiscal year ended Dec 31, 2025
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 23, 2026. Read the filing
By region
United States Revenue$2.21B94%
+53% on the year before ($1.45B)
Rest of the World Revenue$134M5.7%
+399% on the year before ($26.8M)
Total revenue$2.35B+59%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 12,000 words.
From “Overview”, in the company's words
digital, accessible format. The Hims & Hers platforms (collectively, our “platform”) include access to a highly-qualified and technologically-capable provider network, a clinically-focused electronic medical records system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Our digital platform enables access to treatments for a broad range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate.
What the section covers (34 headings)
Overview
Recent Developments
Revenue and Key Business Metrics
Key Factors Affecting Results of Operations
New customer acquisition
Retention of customers
Investments in growth
Expansion into new specialties
Non-GAAP Financial Measures
Basis of Presentation
Components of Results of Operations
Revenue
Cost of revenue
Gross profit and gross margin
And 20 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 23, 2026 and Form 10-Q filed Nov 9, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
When insiders usually buy
Last results
Nov 9, 2026
Within the 30 days after it, until Dec 9, 2026
Next results, expected
Feb 22, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Hims & Hers Health's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Hims & Hers Health's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Owners above 5%
Latest filing Nov 16, 2026
Nobody is above 5% on the latest filings: every recent filer has reported going below the line.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Since Nov 19, 2025, HIMS is down 59.3% and the index fund is up 4.1%: 63 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much HIMS moves
A usual day
±3.2%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
13.0%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−16.6%Nov 10, 2026
Largest one-day rise
+40.8%Mar 9, 2026
Deepest fall of the year
−63.7%From the close of Dec 4, 2025 to Feb 27, 2026.
Days of 5% or more
77Out of 252 sessions, in either direction.
Beta 2.6(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Fails to deliver: 46K shares (about $1.29M) were not delivered on time for settlement on Oct 26, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 45.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (15.1% on ATS, 30.8% with other brokers), below its 26-week average of 48.9%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (12.0%), UBS ATS (11.2%), MS TRAJECTORY CROSS (ATS-1) (6.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Feb 23, 2026, compared with the one filed Feb 24, 2025. Read the filing
New risk factors in the latest annual report (8 headings)
The planned acquisition of Eucalyptus is subject to conditions, some or all of which may not be satisfied or completed on a timely basis, if at all.
Our plans for funding the Proposed Acquisition may be adversely affected to the extent there are lower-than-expected operating results or significant financial market disruptions.
We may not realize the benefits, including growth opportunities, that are anticipated from the Proposed Acquisition.
FDA has issued warning letters related to specimen-collection kits, and similar enforcement activity directed at our products or suppliers could materially and adversely affect our business.
FDA regulation of laboratory developed tests (“LDTs”) and regulation by other countries of diagnostic offerings could materially and adversely affect our business.
If any of the sample collection kits we use are considered prescription medical devices, we may be required to obtain additional state licenses to distribute such devices, and failure to obtain or maintain these licenses could adversely affect our operations.
Perceptions regarding the safety, efficacy, and quality of compounded drugs may significantly harm our business, financial condition, and results of operations.
We have been, and in the future may be, subject to actions and public statements by U.S. federal and state government officials and agencies, which could materially and adversely affect our business, financial condition, results of operations and reputation.
Legal proceedings (Item 3)
In addition to the legal matters described in Note 14 – Commitments and Contingencies included in Part II, Item 8 of this Annual Report on Form 10-K, we are, from time to time, a party to litigation, various claims, and other legal and administrative proceedings arising in the ordinary course of business. Some of these claims, lawsuits, and other proceedings may involve highly complex issues that are subject to substantial uncertainties, and could result in damages, fines, penalties, non-monetary sanctions, or relief.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 23, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.